The strongest case for tyrosine is narrow and real: protect working memory and reaction time when an acute stressor is unavoidable. Two grams, on an empty stomach, 30โ60 minutes before. The cost is trivial and the side effects are mild. The catch is that almost every other claim on the supplement bottle โ daily energy, mood, thyroid support, dopamine optimisation โ is marketing the trial evidence does not back. Treat it as on-demand cognitive insurance, not a daily habit.
Your brain runs on a small set of signalling chemicals, and two of them โ dopamine and noradrenaline โ share a starting material called tyrosine. The body makes tyrosine from another amino acid (phenylalanine) and you also get it from any protein-rich food: cheese, beef, fish, eggs, soy. Inside neurons, an enzyme called tyrosine hydroxylase takes the precursor and turns it into the first step of the dopamine pathway, which the brain then converts onward to noradrenaline Fernstrom 2007.
The trick is that this enzyme is normally about three-quarters saturated with tyrosine already. Adding more substrate to a near-full enzyme does not speed it up โ that is why a tyrosine pill on a relaxed afternoon feels like nothing. Add real stress, though, and the picture changes. Cold exposure, sleep deprivation, and sustained high-stakes attention all push noradrenergic neurons to fire fast and release neurotransmitter faster than the resting pool can be rebuilt. In rats, the same dose of tyrosine that does nothing at rest raises brain catecholamine output specifically in stressed animals Carlsson 1978. The clinical translation: tyrosine is a stand-by raw material that only matters when the factory is running flat out.
What the trials actually found
The cleanest signal in the literature comes from acute, controlled stress. Cold, sleep loss, multitasking โ the conditions a soldier, a clinician, or anyone facing a bad night actually meets. Across about a dozen small randomised trials over twenty years the direction of effect has been consistent.
The pattern is striking: tyrosine works when the stressor is real, and not otherwise. The Mahoney evidence assessment for the US military reviewed ten randomised trials and four controlled trials and graded a weak recommendation in favour for cognitive performance under acute stress โ all studies pointed the same way, but the trials were small, the stressors varied, and no Cochrane-tier consensus has emerged Mahoney 2015. A parallel review of the broader cognitive-control literature concluded the same demand-dependent pattern: benefit emerges under depletion, fades at rest Jongkees 2015.
At rest in unstressed young adults the effect is modest. Two grams in orange juice improved a convergent-thinking puzzle but did nothing for brainstorming Colzato 2014. Task-switching improved on the same dose Steenbergen 2015. In older adults the response inverts: rising tyrosine doses worsened working memory in a dose-dependent way, possibly because age-related dopamine systems aren't substrate-limited the same way van de Rest 2017.
The trials that failed are worth knowing too. A double-blind antidepressant trial at 100 mg/kg per day for four weeks found no benefit versus placebo or imipramine Gelenberg 1990. An open trial in adult ADHD saw initial response in eight of twelve patients but the effect was gone by week six as tolerance developed Reimherr 1987. Heat-and-exercise trials are split โ one showed a 15% improvement in cycling time to exhaustion Tumilty 2011; the same lab's later self-paced trial showed nothing Tumilty 2014, and a 2025 trial in soccer players found no effect Avraam 2025. The military SERE-school trial at 300 mg/kg found no mood effect under interrogation stress and a small rise in anger ratings Morgan 2014.
Put together, the honest picture: a small, replicated cognitive protection for the specific use case of an unavoidable acute stressor in a healthy young adult โ not a generalised mood, energy, or thyroid effect.
The cost of skipping it on the wrong night
Most days the stake is zero. Tyrosine does not protect the unstressed; missing it on a normal Tuesday costs you nothing detectable. The stakes show up on the small number of nights the rest of the catalogue tells you to avoid and that life makes you have anyway.
The on-call shift that started at 11 p.m. and ran into a 6 a.m. case. The cross-continent flight followed by a presentation. The exam two days after a sick child. The deep-cold field day. The version of you that walked into those without tyrosine is the version whose working memory was already eroding by hour four โ the version that read the same paragraph twice, missed the verbal cue, picked the wrong dose, took a beat too long to react. The trial literature does not show that tyrosine prevents all of that; it shows that it preserves a slice of the cognitive performance that decays first, for about three hours, in a measurable way Mahoney 2007, Neri 1995.
The stake is not transformative. It is the difference between a slightly worse and a slightly better version of you on the wrong night โ held, on the trial data, for around the period when judgment matters most. People around you don't see the chemistry; they see whether you caught the thing, called the right code, signed the right line. For the handful of nights a year that actually carry weight, the asymmetry is uncomfortable: the cost of taking it is a few cents and one swallow; the cost of skipping it is a faculty you already know decays under load.
How to actually take it
The dose with the most replication is 100 to 150 milligrams per kilogram of body weight โ about 7 to 10 grams for a 70 kg adult. That is a lot of powder, and most consumer protocols and the rest-condition cognitive trials use a flat two grams, which is roughly 30 mg/kg and still produces measurable effects on convergent thinking and task switching in healthy adults Colzato 2014, Dimitriou 2024. Two grams is the sensible civilian default for a single high-stakes session; the larger military doses make sense when the stressor is severe and sustained.
The form sold in capsules is plain L-tyrosine; N-acetyl-L-tyrosine (NALT) is the marketing alternative that promises better absorption but in practice converts to free tyrosine inefficiently and produces lower plasma rises than the plain amino acid at the same dose. Buy plain L-tyrosine powder or capsules; treat NALT marketing as marketing.
When not to take it
Common side effects at therapeutic doses โ mild and uncommon: nausea, heartburn, headache, occasional irritability. The SERE-school trial saw a small rise in anger ratings on a very high dose Morgan 2014; worth knowing if you're already wound tight before a stressor.
What the supplement aisle gets wrong
Three claims drive the market and none of them is what the trials show.
"Tyrosine boosts dopamine." At rest, in a healthy person, it does not. The enzyme that converts tyrosine to L-DOPA is already roughly 75% saturated; loading more substrate onto a near-full enzyme does not change the output rate. The boost only appears when noradrenergic neurons are firing fast enough to draw the pool down โ under cold, sleep loss, or sustained acute stress Carlsson 1978, Jongkees 2015. The "dopamine support" framing on the bottle is selling you something that requires the stressor you're trying to avoid.
"Tyrosine supports thyroid function." Tyrosine is the structural backbone of T3 and T4 โ that part is real. The leap to "more tyrosine equals more thyroid hormone" is not. In iodine-replete adults the bottleneck on thyroid synthesis is iodine, selenium, and the gland's own regulation, not the amino acid; no trial in euthyroid people has shown supplementation moving TSH, T3, or T4 meaningfully. If your thyroid is sluggish, the question is autoimmune Hashimoto's, iodine intake, or under-replacement on levothyroxine โ not tyrosine.
"Tyrosine treats depression / ADHD." A four-week double-blind trial at 100 mg/kg/day in major depression found no antidepressant effect Gelenberg 1990. The often-cited open ADHD trial saw initial response in eight of twelve adults that collapsed by week six as tolerance developed Reimherr 1987. Tyrosine is not a clinical treatment for either condition; daily dosing is the way to extract the smallest possible benefit from it.
Why "I tried it and it did nothing"
Most "tyrosine did nothing for me" reports collapse to one of three things, and all three are fixable.
- Taken with a protein meal. The other large amino acids in a steak or a protein shake compete with tyrosine for the transporter that gets it across the blood-brain barrier. If you took two grams alongside lunch, the brain rise was a fraction of what it would have been on an empty stomach.
- Taken without a real stressor. On a normal day, with normal sleep, in a normal mood, the catecholamine pool is already adequate โ the precursor isn't the bottleneck. Tyrosine taken before a relaxed afternoon of email does very little because there is no depletion to repair. The trial signal lives under cold, sleep loss, or sustained multitasking Jongkees 2015.
- Taken daily. Chronic dosing is not what the trial literature tested. The single chronic-dosing study that did exist saw tolerance develop in six weeks Reimherr 1987. Use it on the days the stressor is real; let the pool reset on the days it is not.
The fourth, rarer failure mode: you are over 60. The trial that scaled tyrosine doses in healthy older adults found working memory got worse, not better, as the dose rose van de Rest 2017. The trial evidence behind the on-demand use case lives in young adults; in older adults the story is murkier and the on-demand framing is not safe to copy across.
What else is on the on-demand shelf
If the use case is "I have an unavoidable cognitive stressor and want a small, evidence-backed acute boost," tyrosine is one option. The shelf has three other things on it worth comparing honestly.
- Caffeine (50โ200 mg) is the gold standard for acute alertness and vigilance. Decades of converging trials, larger effect sizes than tyrosine, but it builds tolerance, it disrupts subsequent sleep if taken past noon, and it is not what the cold-and-multitasking literature studied.
- L-theanine (100โ200 mg, often paired with caffeine) reduces stress markers and smooths attention; the evidence base is smaller than caffeine's but reasonably consistent.
- Modafinil is stronger than all three for sleep deprivation, has direct military trial evidence, but it is prescription-only and carries non-trivial side effects.
The honest framing: tyrosine is a complement, not a replacement. For a vigilance task at 4 a.m., caffeine first. For multi-hour cold work or all-night sustained-attention shifts where caffeine alone isn't enough and where you don't want the wired-without-focus quality of more caffeine, tyrosine adds. The two have been studied together in military operational settings and behave additively, not antagonistically.
Related
- Caffeine โ the larger, more reliable acute-alertness lever; the natural co-stack for sustained-attention work.
- L-theanine โ pairs with caffeine for smoother attention under stress.
- Sleep debt โ the upstream factor tyrosine is buying you cover for; on-demand precursor cannot replace the eight hours.
- Modafinil โ the prescription-only step up for genuine sleep deprivation when amino-acid precursors aren't enough.
- Thyroid screening โ the right place to chase "tired and slow" symptoms, rather than at the tyrosine bottle.
Substance and claimed effects
L-tyrosine is a non-essential aromatic amino acid synthesised in the body from phenylalanine and obtained in the diet from protein-rich foods (cheese, soy, beef, fish, eggs). It is the rate-limiting precursor for catecholamine synthesis: tyrosine hydroxylase converts it to L-DOPA, which is decarboxylated to dopamine and then beta-hydroxylated to noradrenaline (and onward to adrenaline) Fernstrom & Fernstrom 2007. The same amino acid, iodinated on thyroglobulin tyrosyl residues by thyroid peroxidase, forms the backbone of T3 and T4. Under normal conditions tyrosine hydroxylase is approximately 75% saturated with substrate, so dietary tyrosine is generally not rate-limiting; under sustained sympathetic drive (cold, acute psychological stress, sleep loss, sustained multitasking) catecholamine release outpaces replacement and the precursor supply becomes load-bearing Carlsson & Lindqvist 1978, Jongkees et al. 2015.
The supplement's claims, in roughly descending order of evidentiary weight: preservation of working memory and other executive-function metrics under acute environmental or psychological stress; preservation of vigilance during one night of sleep deprivation; modest improvements in convergent thinking and task-switching at rest in healthy young adults; mood preservation under combat-style stress; and assorted long-tail claims (depression, ADHD, weight loss, libido) that the trial evidence does not support. The entry covers each of these honestly, scored on the substance's actual delivery rather than the marketing surface area.
Evidence by addressing question
Mechanism
Catecholamine neurons under high firing rates show depletion of vesicular dopamine and noradrenaline; tyrosine hydroxylase activity is partly regulated by substrate availability when neurons fire fast, and supplemental tyrosine has been shown in rodents to raise brain catecholamine synthesis specifically in stressed but not resting animals Carlsson & Lindqvist 1978, Fernstrom & Fernstrom 2007. The clinical translation: under rest conditions tyrosine usually does nothing, because the pool is already adequate; under stress, when noradrenergic neurons are firing fast and the pool is being drawn down, the precursor becomes rate-limiting and exogenous tyrosine sustains synthesis.
This is the dominant explanation for the trial pattern observed across two decades: stress is the necessary cofactor for the cognitive benefit. Tyrosine competes with the other large neutral amino acids (phenylalanine, tryptophan, valine, leucine, isoleucine, methionine) for transport across the blood-brain barrier via the LAT1 transporter; a high-protein meal consumed alongside the dose blunts the rise in brain tyrosine because the competing LNAAs go up too. Empty-stomach dosing avoids this Fernstrom & Fernstrom 2007.
The thyroid mechanism is biochemically distinct: tyrosyl residues on thyroglobulin are iodinated and coupled by thyroid peroxidase to form T3 and T4 within the colloid. Free dietary tyrosine is not normally limiting for this pathway in iodine-replete humans, which is why supplementation does not predictably move thyroid hormone levels in euthyroid people; the relevance of tyrosine to thyroid function is structural rather than dose-responsive.
Evidence
The cleanest evidence comes from acute, controlled stress paradigms in healthy young adults. Banderet and Lieberman (1989) exposed soldiers to combined cold (15 ยฐC) and hypobaric hypoxia (4200โ4700 m) for four hours after 100 mg/kg tyrosine or placebo; tyrosine reduced cold sensation, headache, and fatigue and partially preserved performance on a cognitive battery Banderet & Lieberman 1989. Mahoney et al. (2007) replicated the working-memory protection during cold-water immersion at 10 ยฐC with 150 mg/kg given twice (300 mg/kg total split dose) Mahoney et al. 2007. O'Brien et al. (2007) reported parallel results during body cooling O'Brien et al. 2007. Neri et al. (1995) gave 150 mg/kg (split) during one night of total sleep deprivation in military personnel and saw a significant reduction in vigilance lapses and improved psychomotor performance for ~3 hours Neri et al. 1995. Thomas et al. (1999) gave 150 mg/kg to young adults one hour before a demanding dual-task battery in healthy young adults and saw improved working-memory accuracy specifically during the multitasking condition, not the single-task control Thomas et al. 1999. Deijen and Orlebeke (1994) and Deijen et al. (1999) reported memory and blood-pressure benefits under combat-training stress at 2 g/day Deijen & Orlebeke 1994, Deijen et al. 1999.
Two reviews summarise the field: Mahoney et al. (2015) graded the literature as a "weak recommendation in favour" for cognitive performance under acute stress (10 RCTs and 4 controlled trials, all positive on the cognitive endpoint, but heterogeneous in dose, stressor, and measure) Mahoney et al. 2015. Jongkees et al. (2015) reviewed the broader cognitive-control literature and concluded that benefit is conditional on demand: at rest, healthy young adults show little or no effect; under depletion (stress, demanding multitasking) the benefit emerges Jongkees et al. 2015.
Rest-state benefit in healthy young adults exists but is small. Colzato et al. (2014) gave 2 g in orange juice and saw improvement on a convergent-thinking task (Remote Associates Test) but not on divergent thinking Colzato et al. 2014. Steenbergen et al. (2015) saw task-switching benefits at 2 g Steenbergen et al. 2015. In older adults the picture inverts: van de Rest et al. (2017) showed a dose-dependent worsening of n-back performance with rising tyrosine in healthy older adults, suggesting catecholaminergic ceiling effects in age-related dopamine decline van de Rest et al. 2017.
Exercise-and-heat is mixed. Tumilty et al. (2011) reported a 15% improvement in time-to-exhaustion in cycling at 30 ยฐC after 150 mg/kg Tumilty et al. 2011; the same group's later trial in self-paced exercise found no effect Tumilty et al. 2014. A recent 2025 trial in soccer players found no benefit on intermittent high-intensity work in heat Avraam et al. 2025. Dimitriou et al. (2024) gave 2 g before a VR active-shooter drill and saw fewer missed Stroop responses but no shift in stress biomarkers Dimitriou et al. 2024.
The chronic-condition trials are largely negative. Gelenberg et al. (1990) randomised 65 outpatients with major depression to 100 mg/kg/day vs imipramine vs placebo for 4 weeks; tyrosine raised noradrenergic metabolite excretion but produced no antidepressant effect Gelenberg et al. 1990. Reimherr et al. (1987) saw initial response in 8 of 12 adults with residual ADHD that disappeared by week six as tolerance developed Reimherr et al. 1987. Morgan et al. (2014) tested 300 mg/kg in SERE-school interrogation stress; mood and cortisol were largely unchanged and anger ratings rose slightly Morgan et al. 2014.
Protocol
Doses studied range from ~100 to 300 mg/kg as a single oral load. For a 70 kg adult that is 7โ21 g, far above what is sold in capsules. The most reliably effective acute-stress doses are 100โ150 mg/kg, equivalent to roughly 7โ10 g for an adult โ but most consumer protocols and the cleanest cognitive-control studies in non-extreme stress use 2 g flat, which is what Colzato and Steenbergen used and is roughly 30 mg/kg Colzato et al. 2014, Dimitriou et al. 2024. Plasma peaks 1โ2 h post-dose; brain effects are present at 1 h and last roughly 3 h van de Rest et al. 2017. Practical guidance: 500 mg to 2 g taken 30โ60 min before the stressor, on an empty stomach (a high-protein meal in the previous two hours blunts the brain rise via LNAA competition). For longer stressors (multi-hour cold, all-night vigilance) the cleanest protocols give a split dose every 3โ4 h.
Contraindications
Three serious ones and a handful of mild ones. (1) Monoamine oxidase inhibitors (phenelzine, tranylcypromine, selegiline, moclobemide, linezolid which is also an MAOI): combining tyrosine with an MAOI carries a credible hypertensive-crisis risk through unopposed catecholamine accumulation, and is treated as a contraindication. (2) Active hyperthyroidism / Graves' disease: tyrosine supplies the structural substrate for thyroid hormone synthesis, and while it does not move euthyroid TSH in trials, providing the substrate in a state of pathological overdrive is contraindicated. (3) Levodopa for Parkinson's disease: tyrosine and levodopa compete for the same LNAA transporter at the gut and at the BBB, and supplementation can blunt levodopa response. Lesser flags: melanoma history (tyrosine is the substrate for melanin via tyrosinase; theoretical concern, no trial evidence of acceleration); pregnancy and lactation (no safety data above food intake); thyroid medication generally (timing separation recommended). Reported side effects at therapeutic doses are mild and uncommon: nausea, heartburn, headache, occasional irritability.
Misconceptions
The dominant supplement-marketing claim โ that tyrosine is a baseline mood, libido, energy, or weight-loss enhancer โ is not what the trials show. The substance does very little in unstressed, well-fed, well-rested healthy adults. The misconception that it "raises dopamine" in a useful way at rest collides with the rate-limiting biology: hydroxylase is already 75% saturated, and giving more substrate to a saturated enzyme does not change product flux Carlsson & Lindqvist 1978. A parallel misconception treats it as a thyroid booster; there is no trial evidence that tyrosine supplementation moves T3, T4, or TSH in euthyroid people, and Hashimoto's autoimmunity, iodine status, or selenium status drive most clinically relevant thyroid outputs, not tyrosine availability. A third โ that the ADHD trial (Reimherr 1987) supports tyrosine as an Adderall substitute โ ignores the tolerance result: response disappeared by week six Reimherr et al. 1987.
Failure modes
Most "tyrosine did nothing for me" reports collapse to one of three: (1) taken with a protein meal, blunting BBB transport via LNAA competition; (2) taken at rest with no acute stressor, where catecholamine pool is already adequate and adding precursor changes nothing detectable; (3) chronic daily dosing, where tolerance / homeostatic adaptation eats the acute effect (Reimherr's ADHD pattern is the canonical example) Reimherr et al. 1987. The substance is best understood as an acute, on-demand intervention for known stressors, not a daily supplement.
Alternatives
For acute cognitive performance under stress, caffeine (50โ200 mg) has more reliable effect sizes and decades of converging data, though it tolerates and disrupts subsequent sleep. Modafinil shows stronger sleep-deprivation effects in military trials but is prescription-only. L-theanine (100โ200 mg, often with caffeine) reduces stress markers and improves attention; combinations are common. For chronic stress resilience the candidates are sleep, exercise, and structural load reduction, not amino acid precursors.
Population variability
Stressor presence is the major moderator (the entire effect size collapses without it). Age inverts the response โ older adults can lose working-memory performance at the same doses that help young adults, plausibly because dopaminergic systems in age-related decline are not rate-limited the same way van de Rest et al. 2017. Baseline diet matters: meat-heavy diets already deliver 2โ6 g tyrosine/day from food, leaving less room for supplement-driven changes. Individual COMT genotype likely modulates responsiveness through baseline dopamine clearance differences, though this hasn't been definitively trialled.
Stakes
The honest stakes are narrow: a single exam, a single overnight on-call, a single cold-weather event, a single VR-shooter-type acute task. Skipping tyrosine in those contexts is the loss of a small-to-moderate, real, replicated working-memory protection. Outside those contexts the stake is approximately zero โ daily life is not the trial paradigm.
Payoff
The honest payoff is the specific cognitive insurance for known acute stressors: the all-nighter you can't reschedule, the cold-weather field day, the high-stakes meeting after three hours of sleep. Onset is roughly 30โ60 minutes; duration roughly 3 hours; cost roughly $0.10 per dose at consumer prices. The everyday-energy and chronic-mood payoff that supplement marketing implies is not what the literature supports.
Credibility range
Optimist case. Across two decades, a coherent body of small, reasonably-controlled trials in cold, hypoxia, sleep loss, and multitasking shows the same direction of effect in the same direction-of-fit: tyrosine preserves working memory and reduces vigilance lapses under conditions where catecholamine release is high and prolonged. The mechanism is well understood and rests on tyrosine hydroxylase substrate dependence in fast-firing neurons. Side effects are minimal. For a soldier, an emergency clinician, a surgeon on call, or a parent on a sleepless stretch, the cost-benefit is favourable: a few dollars, no abuse potential, no scheduling complication, modest but real protection of a faculty that decays first under load. The Mahoney 2015 evidence assessment, the field's most systematic appraisal, made a positive (weak) recommendation Mahoney et al. 2015.
Skeptic case. The trial literature is largely military, small (often n < 30), heterogeneous in stressor and measure, and from a narrow set of labs. Many failed-replication or null trials sit alongside the positives (Tumilty 2014, Avraam 2025, Morgan 2014, Gelenberg 1990, the older-adult arm of van de Rest 2017) Tumilty et al. 2014, Avraam et al. 2025, Morgan et al. 2014, Gelenberg et al. 1990, van de Rest et al. 2017. The base rate of well-powered effect on cognition is small. The Cochrane-quality consensus does not exist. Public marketing has overshot the data by an order of magnitude โ "dopamine booster", "thyroid support", "energy" โ categories the trial evidence does not establish.
Author's call. Real, narrow, replicated effect on cognition under acute stress in healthy young adults, with strongest evidence in cold/sleep-loss/multitasking. Negligible effect at rest. No support for chronic mood, energy, or thyroid claims. Score: evidence 3 (small trials, consistent direction, narrow context, no large RCT or guideline backing). Controversy modest (1) โ there is no real fight in the field; the disagreement is between the trial reality and the supplement market.
Stakeholder and incentive map
- Supplement industry. Strong commercial incentive to market tyrosine as a daily nootropic and "dopamine support" โ categories the trial evidence does not establish but that command price premiums and recurring purchases.
- Military and operational medicine. The most rigorous research source. USARIEM (Banderet, Lieberman, Mahoney, Tharion) generated most of the cold and sleep-deprivation literature; military operational-readiness funding is the incentive.
- Academic cognitive-control labs. Colzato, Hommel, Jongkees and colleagues in Leiden have driven the rest-condition cognitive-flexibility literature; the incentive is academic (probing dopaminergic cognition with a clean precursor lever).
- Skeptic / counter-incentive. Mainstream nutrition and endocrinology bodies treat tyrosine as a non-essential amino acid covered by ordinary diet and do not endorse supplementation; no major guideline (AHA, USPSTF, NICE, AASM, ATA) recommends it.
Population variability
- Age: the response inverts in older adults; cognitive performance can worsen on higher doses van de Rest et al. 2017.
- Baseline diet: meat-and-dairy-heavy diets already supply 2โ6 g/day from food; supplement marginal effect is smaller in this group.
- Stressor presence: the largest moderator. No stressor, no effect.
- COMT and other dopaminergic genotypes: plausibly modulate response through baseline catecholamine clearance; not definitively trialled.
- Medication context: MAOI users, Parkinson's patients on levodopa, and Graves' patients are contraindicated, not variable-responding.
Knowledge gaps
- No large, well-powered RCT in a civilian high-stress occupation (ER medicine, on-call surgery, parents of newborns, traders during volatility).
- No head-to-head against caffeine, modafinil, or L-theanine for acute cognitive insurance.
- No long-term safety data above 3 months at chronic supplemental doses.
- No good characterisation of when tolerance to chronic dosing develops (Reimherr's six-week ADHD finding is the only datum and it is from a different patient population) Reimherr et al. 1987.
- No trial-quality test of the marketed claims (libido, energy, weight loss, thyroid support).
- Mechanism in humans is inferred from rodent data plus precursor-response observation; direct human neurochemistry under stress is still thin.
Scope vs. brief. The brief named cognition under stress, working memory, mood, alertness, and thyroid hormone production. The article covers all five honestly, but lands very different scores: focus (3) carries the real signal, energy and mood are 1 each (acute, narrow), and thyroid was scored 0 because the trial evidence does not show supplemental tyrosine moving thyroid hormones in euthyroid people. The thyroid claim is addressed directly in misconceptions rather than dropped โ the brief named it, so the article must engage it, even if to debunk.
Why do rather than know. The honest action is to keep a jar on the shelf and use it on the specific nights that meet the trial use case. Pure know would understate the actionable on-demand protocol; do + as-needed captures the asymmetry.
Why evidence is 3 and not 4. The Mahoney 2015 evidence assessment gave a weak-favourable recommendation, not a strong one. The trial pool is small (n typically < 30), military-skewed, and from a narrow set of labs. The signal is consistent in direction but the evidence base does not clear the bar for "one good RCT or consistent observational data; clinical community broadly aligned" โ there is no clinical community position, because mainstream medicine treats tyrosine as a non-essential amino acid covered by diet.
Rating difficulty on mood. The mood call was the hardest. The acute-stress trials show real preservation of subjective fatigue, headache, and tension; the Gelenberg depression trial is firmly negative; the SERE-school trial showed a small increase in anger ratings. Net call: mood 1, captured as "acute stress buffer, not a depression treatment." Reasonable reviewers could land at 0 or 2.
Contraindications. Used the thyroid-condition token because hyperthyroidism / Graves is the load-bearing one and the contraindications vocabulary is closed. MAOI use, levodopa interaction, and melanoma history are flagged in the article body but don't have dedicated tokens in the meta vocabulary โ flagging in case the closed list should be extended.
NALT note. The protocol section actively recommends against N-acetyl-L-tyrosine. This is a marketing-vs-pharmacokinetics call, not a trial-evidence one; happy to soften if the reviewer disagrees, but the bioavailability literature broadly does not support NALT's premium pricing.
Dream narrative. Written despite the entry scoring well below 40, because the relief / not-being-conned lever is honest and load-bearing for the tagline. Skipping it would have produced a more neutral tagline; the entry is a narrow-use-case supplement whose hook is precisely the gap between trial reality and marketing reality.
Future-link candidates. Caffeine, L-theanine, modafinil, sleep debt, thyroid screening, ApoE / COMT genotype testing (the dopaminergic-genotype angle isn't trial-quality yet but will be a future link if it lands).
Separate-entry candidates. Phenylalanine (the upstream precursor; different evidence base, partially overlapping mechanism). NALT as a separate product entry if the supplement market for it grows enough to warrant a debunking entry.
L-Tyrosine
A few cents per dose. Annual spend well under $50 even with regular use.
One pill, 30โ60 minutes before the stressor, on an empty stomach. Forgetting the timing kills the effect.
The most reliable effect: protects working memory when stress, cold, multitasking, or sleep loss would otherwise erode it.
Two decades of small, consistent trials in military and lab settings. No giant RCT, but the signal is real and the direction is the same one every time.
A small acute buffer against the felt edge of cold, hypoxia, or one bad night โ not an everyday wellness lift.
Cuts the fatigue and vigilance lapses of one rough night. Acute only; nothing for daily tiredness.
Blunts the irritability and tension of an acute stressor; not a depression treatment, despite the marketing.